Rutherford-based Glucotrack Inc., a medical device company focused on diabetes technology, will present safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Amsterdam.
The company’s intravascular CBGM system is designed to measure glucose directly from the blood rather than interstitial fluid, potentially offering greater accuracy and real-time monitoring without on-body wearables. The device is implantable for up to three years, providing a less intrusive and more convenient glucose monitoring solution for diabetes management.
“We are excited to showcase these significant trial results, which support our novel approach to continuous glucose monitoring,” said Paul V. Goode, PhD, president and CEO of Glucotrack. “This technology could represent a transformative advancement in diabetes care.”
Glucotrack’s study findings will be presented at ATTD and made available on the company’s website following the conference.
